NCT01218217已完成2 期
A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Michael Hoelscher2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.
研究概览
简要总结
SQ109 was developed with the aim of shortening TB treatment and providing new drugs for resistant TB. The drug has demonstrated efficacy in toxicology studies and an acceptable safety profile in first-in-man studies. The objective of this study is to evaluate the extended early bactericidal activity (EBA), safety, tolerability, and pharmacokinetics of several doses of SQ109 with or without Rifampicin (RIF) for 14 days in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide signed written informed consent for study participation, including HIV testing (if HIV serostatus is not known or the last documented negative is more than four weeks prior to enrolment).
- •Be eighteen (18) to 64 (inclusive) years of age.
- •Have a body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
- •Have newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
- •Have a chest X-ray which, in the opinion of the Investigator, is compatible with TB.
- •Is sputum positive on direct microscopy for acid-fast bacilli (at least 1+ on the IUATLD/WHO scale (Appendix 3).
- •Is able to produce an adequate spot sputum sample, indicating an overnight sputum volume of at least 10 mL.
- •Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practice two effective methods of birth control when not abstaining from sexual intercourse, unless she and her partner(s) are surgically sterile or she is post-menopausal with no menses for the last 12 months. Preferably, contraceptive measures should be continued until completion of TB treatment, but at least until one month after last dose of IMP, unless she and her partner(s) are sterile (that is, women who have had a bilateral oophorectomy or hysterectomy or have been postmenopausal for at least 12 consecutive months).
- •Two of the following methods may be used, but only one may be hormonal: tubal ligation, vaginal diaphragm, intrauterine device, condom, oral contraceptives, contraceptive implant, combined hormonal patch, combined injectable contraceptive or depot-medroxyprogesterone acetate, partner(s) has had a vasectomy.
- •Male participants must agree to use an adequate method of contraception when not abstaining from sexual intercourse throughout participation in the trial and for 12 weeks after last dose, unless he has had bilateral orchidectomy.
- •A Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs, see Appendix 5)
排除标准
- •Poor general condition where any delay in treatment cannot be tolerated per discretion of Investigator.
- •Treatment with any drug active against MTB within the 3 months prior to Visit 1 (this includes, but is not limited to INH, EMB, RIF, PZA, amikacin, cycloserine, rifabutin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, thioacetazone, capreomycin, fluoroquinolone, thioamides, metronidazole).
- •Sputum isolate is resistant to RIF as detected by rapid assay from native sputum
- •A history of allergy to the IMP or related substances.
- •Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the investigator.
- •A history of previous TB.
- •Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease.
- •Laboratory parameters done at, or within 14 days prior to, screening:
- •Serum amino aspartate transferase (AST) and/or serum alanine aminotransferase (ALT) activity >3 times the upper limit of normal
- •Serum total bilirubin level >2.5 times the upper limit of normal
- •Serum creatinine level >2 times the upper limit of normal
- •Complete blood count with hemoglobin level <7.0 g/dL
- •Platelet count <50,000/mm3
- •Serum potassium <3.5 meq/L
- •History, presence, or evidence of a neuropathy or epilepsy.
- •Clinically relevant change s in the ECG such as atrioventricular (AV) block, prolongation of the QRS complex over 120 milliseconds, or of either the QTcF or QTcB interval over 450 milliseconds on the screening ECG.
- •A history of, or current clinically relevant cardiovascular disorder such as myocardial infarction, heart failure, coronary heart disease, hypertension, arrhythmia, or tachyarrhythmia. Family history of sudden death of unknown or cardiac-related cause, or of prolonged QTc interval. Concomitant use of any drug known to prolong QTc interval (including amiodarone, bepridil chloroquine, chlorpromazine, cisapride, cisapride, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, lumefantrine, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine).
- •Diabetics using insulin.
- •Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
- •Any disease or condition in which the use of the standard TB drugs or any of their components is contraindicated, including but not limited to allergy to any TB drug, their components or to the IMPs.
- •Any disease or condition in which any of the medicinal products listed in the section pertaining to prohibited medication (see 4.10.4) is used.
- •Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient. Opiates prescribed for cough relief are not counted as drug abuse.
- •Prior administration of SQ
- •Is pregnant, breast-feeding, or planning to conceive or father a child within one month of cessation of treatment.
- •Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes (including xenobiotics, quinidine, tyramine, ketoconazole, testosterone, quinine, gestodene, metyrapone, phenelzine, doxorubicin, troleandomycin, cyclobenzaprine, erythromycin, cocaine, furafylline, cimetidine, dextromethorphan). Exceptions may be made for subjects that have received 3 days or less of one of these drugs or substances, if there has been a wash-out period equivalent to at least 5 half-lives of that drug or substance.
- •Use of any therapeutic agents within 30 days prior to dosing known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine).
- •Use of systemic glucocorticoids within three months prior to dosing.
- •HIV infection with helper/inducer T lymphocyte (CD4 cell) count of 250 10-6/L.
- •Receiving antiretroviral therapy (ART).
研究组 & 干预措施
SQ109 300 mg + RIF
Experimental
300 mg SQ109 + RIF standard dose daily
干预措施: SQ109 (Drug)
SQ109 300 mg + RIF
Experimental
300 mg SQ109 + RIF standard dose daily
干预措施: Rifampicin (Drug)
SQ109 150 mg + RIF
Experimental
150 mg SQ109 + RIF standard dose daily
干预措施: Rifampicin (Drug)
SQ109 75 mg
Experimental
75 mg SQ109 monotherapy daily
干预措施: SQ109 (Drug)
SQ109 150 mg
Experimental
150 mg SQ109 daily
干预措施: SQ109 (Drug)
SQ109 300 mg
Experimental
300 mg SQ109 daily
干预措施: SQ109 (Drug)
SQ109 150 mg + RIF
Experimental
150 mg SQ109 + RIF standard dose daily
干预措施: SQ109 (Drug)
RIF Mono
Active Comparator
Standard dose Rifampicin monotherapy daily
干预措施: Rifampicin (Drug)
结局指标
主要结局
The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.
时间窗: Daily during first two weeks
次要结局
- Pharmacokinetics(Days 1,2,7,8,14,15)
- The standard EBA (EBA 0-2) of each treatment group, as determined by the rate of change of log Colony Forming Units (logCFU) in sputum over the period Day 0-2 (linear, bi-linear or non-linear regression of logCFU over time).(Day 0 - Day 2)
- Extended EBA (EBA 2-14) of each treatment group, as determined by the rate of change of logCFU in sputum over the periods Day 2-14 (linear, bi-linear or non-linear regression of logCFU over time).(Days 2-14)
- The change in time to positivity (TTP) in the Mycobacterium Growth Indicator Tube (Bactec MGIT 960 system).(Days 0-14)
- Proportion of subjects with serious adverse events and proportion of subjects who discontinue due to an adverse event in each experimental arm.(Entire study period)
研究者
Michael Hoelscher
Professor
Ludwig-Maximilians - University of Munich
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .Small Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT05959694Chia Tai Tianqing Pharmaceutical Group Co., Ltd.107
已完成
2 期
PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood AssayTuberculosisNCT01225640Sequella, Inc.59
进行中（未招募）
2 期
Short-course Regimens for the Treatment of Pulmonary TuberculosisTuberculosis, PulmonaryTuberculosis InfectionNCT05766267Centers for Disease Control and Prevention288
Unknown
2 期
Pharmacogenetics-guided Isoniazid Dosing in TB-HIVTuberculosisNCT05124678Makerere University40
招募中
2 期
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaB-cell LymphomaNCT06566586Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80